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Abstract
Background: TRIM8 plays a key role in controlling the p53 molecular switch that sustains the transcriptional activation
of cell cycle arrest genes and response to chemotherapeutic drugs. The mechanisms that regulate TRIM8, especially in
cancers like clear cell Renal Cell Carcinoma (ccRCC) and colorectal cancer (CRC) where it is low expressed, are still
unknown. However, recent studies suggest the potential involvement of some microRNAs belonging to miR-17-92 and
its paralogous clusters, which could include TRIM8 in a more complex pathway.
Methods: We used RCC and CRC cell models for in-vitro experiments, and ccRCC patients and xenograft transplanted
mice for in vivo assessments. To measure microRNAs levels we performed RT-qPCR, while steady-states of TRIM8, p53,
p21 and N-MYC were quantified at protein level by Western Blotting as well as at transcript level by RT-qPCR. Luciferase
reporter assays were performed to assess the interaction between TRIM8 and specific miRNAs, and the potential effects
of this interaction on TRIM8 expression. Moreover, we treated our cell models with conventional chemotherapeutic
drugs or tyrosine kinase inhibitors, and measured their response in terms of cell proliferation by MTT and colony
suppression assays.
Results: We showed that TRIM8 is a target of miR-17-5p and miR-106b-5p, whose expression is promoted by N-MYC,
and that alterations of their levels affect cell proliferation, acting on the TRIM8 transcripts stability, as confirmed in ccRCC
patients and cell lines. In addition, reducing the levels of miR-17-5p/miR-106b-5p, we increased the chemo-sensitivity of
RCC/CRC-derived cells to anti-tumour drugs used in the clinic. Intriguingly, this occurs, on one hand, by recovering the
p53 tumour suppressor activity in a TRIM8-dependent fashion and, on the other hand, by promoting the transcription of
miR-34a that turns off the oncogenic action of N-MYC. This ultimately leads to cell proliferation reduction or
block, observed also in colon cancer xenografts overexpressing TRIM8.
Conclusions: In this paper we provided evidence that TRIM8 and its regulators miR-17-5p and miR-106b-5 participate
to a feedback loop controlling cell proliferation through the reciprocal modulation of p53, miR-34a and N-MYC. Our
experiments pointed out that this axis is pivotal in defining drug responsiveness of cancers such ccRCC and CRC.
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Background
The efficacy of current cancer treatments is often limited
by the development of therapeutic resistance whose
mechanisms still remain not fully elucidated. This is the
case of clear cell Renal Cell Carcinoma (ccRCC), the
most common subtype of RCC accounting for about
80% of surgical cases. When localized, this cancer type
may be curable with surgery, although a substantial
number of patients have evidence of metastasis at the
time of diagnosis and a relevant number develop sys-
temic recurrence after primary tumour resection [1].
ccRCC is paradigmatic in the way that it is characterized
by exceptionally high resistance to radiation and chemo-
therapy, despite p53 tumour suppressor gene mutations
being particularly rare. In this tumour, specific p53 path-
ways are inhibited by mechanisms, often unknown, other
than mutations of the protein itself, resulting in a pheno-
type characterized by tumourigenesis, chemo-resistance,
invasion and metastasis, that could be reverted by acting
on the inhibiting factors.
Recently, we showed that TRIM8 protein has a prom-
inent role in regulating cancer cell growth in vivo in
ccRCC [2]. TRIM8 is a member of the TRIM/RBCC
protein family, characterized by the presence of a
tripartite motif consisting of a RING finger, one or two
B-box and a Coiled Coil region. A peculiarity of the
proteins belonging to this family is the variety of roles
exerted by each of its members. This characteristic is
due to their structure that enables them to fulfil both
structural and functional tasks. Some TRIM proteins
show a dual role either as oncogene or tumour suppres-
sor, depending on the cellular context [3, 4]. Similarly,
TRIM8 exerts more than one role in quite diverse path-
ways, as in embryonic development and differentiation,
in innate immune response and in a variety of human
cancers [5, 6]. In ccRCC, we demonstrated that TRIM8
is a direct p53 target gene that - through a feedback
loop mechanism - appears to be a pivotal component in
controlling the molecular switch that directs p53 to-
ward transcriptional activation of cell cycle arrest
genes, such as p21 and GADD45 [2]. Noteworthy, we
found that TRIM8 expression level is significantly de-
creased in ccRCC compared to matched non-tumour
tissue, and such a signature was typical of this more
malignant neoplasms, whereas benign oncocytomas
(ROs), for instance, didn’t show it [7].
In our previous paper, we demonstrated that TRIM8
deficit is associated to Loss of Heterozygosity (LOH) of
the TRIM8 locus in ccRCC cell lines; however, cases of
gene-dosage compensation in LOH conditions are known,
therefore we could not exclude other possible mechanisms
involved in TRIM8 expression reduction [7]. Among
these, microRNA regulation of expression showed up as
one of the most interesting, as miR-17-92 cluster targeting
and regulation of TRIM8 mRNA has been recently re-
ported [8, 9]. This cluster is located on chromosome
13q31.3 in the third intron of the C13orf25 gene, and
contains 6 miRNAs (miR-17, miR-18, miR-19a, miR-
20a, miR-19b-1, miR-92-1). The human genome con-
tains two paralogues of the miR-17-92 cluster: 1) the
miR-106b/25 cluster (miR-106b, miR-93, miR-25) is
located on chromosome 7 (7q22.1) in the 13th intron
of the Mini-Chromosome Maintenance gene MCM7);
2) the miR-106a/363 cluster (miR-106a, miR-18b, miR-
20b, miR-19b-2, miR-92-2, miR-363) is located on chromo-
some X (Xq26.2). Together these three miRNA clusters
contain a total of 15 miRNAs constituting four “seed”
families: the miR-17, the miR-18, the miR-19 and the miR-
92 family. While the miR-106a/363 cluster is rarely
expressed in adult human tissues, the miR-17-92 and miR-
106b/25 clusters are emerging as key actors in a wide range
of biological processes including tumorigenesis [10–12].
An increasing number of papers reported that miR-106b-
5p and miR-17-5p, above all the microRNAs of the miR-
17-92 cluster, are overexpressed in many different chemo/
radio-resistant cancers, including ccRCC, glioma and
Colorectal Cancers (CRC). This latter is one of the most
common cancers worldwide and, as in ccRCC, the poor
prognosis is due to late diagnosis and low chemotherapy
response. Therefore, drug resistance poses a great chal-
lenge in this widespread cancer too [9, 13–15].
The mechanisms through which the miRNAs-
TRIM8-p53 axis – whose existence here we postulate
based on the aforementioned observations - may im-
pact chemo-resistance remain largely unknown. More-
over, we hypothesize the presence of an additional
factor in this regulatory axis, that is N-MYC, a well-
known oncogene deregulated in a myriad of human
cancers and placed at the nexus of cell growth, prolifer-
ation, metabolism, and genome stability [16]. Indeed,
the miR-17-92 cluster as well as the MCM7 gene, con-
taining the miR-106b/25 cluster, are transcriptionally
activated by N-MYC [17–20].
In this paper, using two independent cancer cell
models, we unveiled a novel regulatory mechanism
where inhibition of miR-17-5p and/or miR-106-5p leads
to recover TRIM8-mediated p53 tumour suppressor ac-
tivity and strong inhibition of N-MYC-dependent cell
proliferation by p53-dependent N-MYC destabilization
through miR-34a up-regulation. Finally, we demonstrated
the influence of the N-MYC-miRNAs-TRIM8-p53 axis on
the efficacy of cancer treatments in ccRCC and CRC.
Methods
Cells and treatments
The human proximal tubular epithelial cells HK-2 (wild
type p53), the human renal cell carcinoma RCC-Shaw
(ccRCC-derived cell line with wt-p53), the human renal
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carcinoma of BHD (Birt-Hogg-Dubè) origin UOK-257
cells (RCC cell line with mutated p53) and the colon can-
cer cell line HCT116 were cultured in Dulbecco’s modi-
fied Eagle’s medium (D-MEM) plus 10% foetal bovine
serum (FBS), L-Glutamine (2 mM), penicillin (100 U/ml)
and streptomycin (100 μg/ml) at 37 °C, 5% CO2. Nutlin-3
10 μM (Cayman), Cisplatin 7.5 μM (Sigma), Sorafenib
10 μM (SantaCruz) and Axitinib 10 μM (SantaCruz) were
used for 24 h [2, 7, 21].
In particular, Sorafenib and Axitinib are normally
used for treatment of ccRCC patients and are commer-
cially available with the name Nexavar® and Inlyta®,
respectively.
Transfections
2.5 × 105 human HK-2, RCC-Shaw, UOK-257 or HCT116
cells were plated in 6-well plates (60–80% confluency) and
transfected with 50 pmol of miR-17-5p-mimic, miR-106b-
5p-mimic, anti-miR-17-5p, anti-miR-106b-5p or Negative
Control miRNA Mimic (Ambion) using SiPORT NeoFX
Transfection Agent (Ambion). 24 h later cells were treated
with the specific chemotherapeutic drugs (Nutlin-3,
Cisplatin, Sorafenib or Axitinib). 48 h after transfections
cells were collected for MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay or for RNA and
protein extractions.
Four different TRIM8 short hairpin RNAs (Origene™)
were used to silence TRIM8 transcript by adding them
to the medium containing the transfection reagent and
incubating the shRNAs-transfecting agent complex at
room temperature for 20 min before adding it to the cell
cultures for 48 h.
TRIM8 specific shRNAs are here reported:
1) TGATAAGACGGAGGATGTCAGCTTCATGA;
2) AACCTGAAGCTCACCAACATCGTGGAGAA;
3) TAAGATCGGCCACCTGAACTCCAAGCTCT;
4) CGCAAGATTCTCGTCTGTTCTGTGGACAA
Cell proliferation assays by MTT reduction
2 × 105 cells were plated in six-well plates. After treat-
ments, 200 μl of MTT solution (5 mg/ml) were added to
the cells for 4 h at 37 °C. The medium was then re-
moved and the reduced blue formazan crystals were sus-
pended in isopropanol prior to reading the absorbance
at 580 nm. Relative cell proliferation rate was measured
respect to the sample transfected with the Negative Con-
trol miRNA Mimic. The reported data represent the
average of at least three independent experiments and
are shown with their standard deviations. Two-tailed
Student’s T tests were performed to assess the statistical
significance of cell proliferation rate.
Colony suppression assay
2.0 × 105 HK-2, RCC-Shaw, UOK-257 or HCT116 cells
were plated in six-well plates (50–60% confluency) and
transfected with 50 pmol of anti-miR-17-5p, anti-miR-
106b-5p or Negative Control miRNA Mimic (Ambion)
using SiPORT NeoFX Transfection Agent (Ambion).
24 h later cells were treated with the specific chemother-
apeutic drugs (Nutlin-3, Cisplatin, Sorafenib or Axitinib).
48 h after transfections cells were rinsed with PBS, fixed
with methanol for 30 min at room temperature and
stained with Giemsa.
Luciferase reporter assay
To assess miRNA/target interaction, the TRIM8 3’UTR
fragment containing miR-17-5p/miR-106b-5p binding
site wild type or mutant (wt or mut), and the p21 3’UTR
fragment containing miR-17-5p/miR-106b-5p binding
site wild type (wt) were cloned into pMIR Luciferase
reporter vector (Life Technologies) downstream of the
reporter luciferase gene. The genomic fragments were
amplified by PCR using specific primers (available upon
request). Resulting clones were sequenced to verify proper
sequence identity.
2.5 × 105 human HK-2 or HCT116 cells were plated in
six-well plates (60–80% confluency) and transfected with
50 pmol of miR-17-5p-mimic, miR-106b-5p-mimic, anti-
miR-17-5p, anti-miR-106b-5p or Negative Control
miRNA Mimic (Ambion), using SiPORT NeoFX Trans-
fection Agent (Ambion). 12 h later cells were transfected
with pMIR-TRIM8 3’UTR-wt, pMIR-TRIM8 3’UTR-mut
or pMIR-p21 3’UTR and with the pRL SV40 renilla lu-
ciferase vector (transfection control). 42 h later, cells
were lysed by using Passive-Lysis buffer (Promega). Both
firefly and renilla luciferase activities were measured
using the Dual-Luciferase Assay System (Promega)
and quantified on a TD-20/20 Luminometer (Turner
Designs). Firefly luciferase was normalized to renilla
luciferase activity, presented as relative luciferase activity.
The data reported represent the average of at least
three independent experiments and are shown with their
standard deviations.
In vivo xenograft tumour studies
Eighteen age- and sex-matched CD1 nude mice from
Charles River Laboratories were used for these studies.
7 × 106 HCT116 cells were harvested in PBS and
injected subcutaneously on each flank of the nude mice
(cells/flank). Four days later mice were randomized in
three homogenized experimental groups; tumours
thereby generated were treated with 1x109 MOI (multi-
plicity of infection) of each of the three recombinant
adenoviruses expressing HA-TRIM8, HA-RING-TRIM8
or LacZ in sterile PBS, two times per week for three
weeks. The tumours were measured using Vernier
Mastropasqua et al. Molecular Cancer  (2017) 16:67 Page 3 of 16
calipers, and the volume was calculated using a standard
formula (Width2 × Length × 0.5) [22, 23]. After 21 days
from the first treatment mice were sacrificed and tumours
were collected and weighted.
RNA extraction from tissues and cell lines
Tumour and paired adjacent non-tumour renal paren-
chyma samples from a total of 24 patients were used for
this work. Immediately after surgery, tissues were separ-
ately stored and frozen at -80 °C according to a standard
procedure. From histological examination, 20 samples
were classified as clear cell RCCs (10 males and 10 fe-
males; mean age: 63 ± 10.8 years) and 4 were oncocyto-
mas (all males; mean age: 63.25 ± 4.86 years) (Additional
file 1: Table S1). The pathological staging was deter-
mined according to the latest TNM classification and
grading according to Fuhrman. Informed consent to take
part in this study was obtained from all the patients.
The Hospital’s Ethics Committee approved the study.
Collected ccRCC samples were processed for total RNA
extraction from 50 to 100 mg of fresh frozen tissue
using the TRIzol reagent (Life Technologies™). All RNA
samples were purified using the RNeasy Mini kit (Qiagen®)
according to the manufacturer’s instructions.
Xenograft tumours were immediately frozen in liquid
nitrogen after excision. Tissues were homogenated by
Tissue Lyser II (20Hz; 2 min, repeated two times) in
RLT buffer (Qiagen®). Total RNA was extracted using
the miRNeasy kit (Qiagen®) according to the manufac-
turer’s instructions.
HK-2, RCC-Shaw, UOK-257 or HCT116 cells were
plated in 50-mm culture dishes at a confluence of 5×105
cells/ml. After treatments, total RNA (including miR-
NAs) was extracted using the miRNeasy kit (Qiagen®),
according to the manufacturer’s instructions.
Total RNA extracted from patients, tumour xenografts
and cultured cells were quantified using the NanoDrop™
1000 Spectrophotometer (Thermo Scientific) and the
quality was analysed by 2100 Bioanalyzer (Agilent
Technologies).
RT-qPCR analysis
For mRNA quantification, reverse transcription of
500 ng of total RNA was performed using QuantiTect®
Reverse Transcription kit (Qiagen®), according to the
manufacturer’s instructions. TRIM8 and p21 expression
levels were measured in triplicate by using TaqMan®
assays. Expression levels were calculated relative to the
expression levels of RPL13 gene, according to the ΔΔCt
method.
For miRNAs quantification, reverse transcription of
10 ng of total RNA was performed using TaqMan
MicroRNA RT Kit (Life Technologies™), according to
the manufacturer’s instructions. miR-17-5p, miR-106b-5p,
miR-106a-5p, and miR-34a expression levels were mea-
sured in triplicate by TaqMan MicroRNA Assay (Life
Technologies™) using the ABI PRISM 7900HT platform
(Applied Biosystems®, Life Technologies™) and normalized
to snU6 expression (Life Technologies™).
The reported data represent the average of at least
three independent experiments and are shown with their
standard deviations or errors. Two-tailed Student’s T
tests were performed to assess the statistical significance
of gene expression levels differences observed. In this
study, a p-value less than 0.05 was considered to be
statistically significant.
Correlation analysis of TRIM8 and miR-17-5p/miR-
106b-5p expression levels was performed using GraphPad
Prism 7 (GraphPad Software, San Diego, CA). First, ex-
pression data (expressed as ΔCt = CtGOI - CtHKG(s)) were
tested for normality of distribution by D’Agostino-Pearson
omnibus K2 test and Shapiro-Wilk test. Then, we com-
puted Pearson correlation coefficients or nonparametric
Spearman correlation (with p-values) depending on the
deviation from Gaussian distribution. Linear regression
plots were generated as scatter plots with a trendline by
Excel (Microsoft).
Protein extraction from cell lines and Western blot analysis
Cells were plated in 100-mm culture dishes at a density
of 5×105 cells/ml. After treatments, cells were lysed and
proteins were extracted as previously described [24].
Tumour masses from xenografts were homogenated in
RIPA buffer plus proteinase inhibitors by Tissue Lyser II
(25 Hz; 2 min) while tissue samples from patients were
homogenated in ice-cold sample buffer (8 M urea, 4%
CHAPS, 40 mM Tris-base, 65 mM DTT containing a
protease inhibitor cocktail). After 30 min incubation on
ice, samples were centrifuged at 13,000 x g at 4 °C. The
surnatants were collected in new tubes and protein
content was assayed by Bradford dye-binding method
(BioRad Protein assay).
For immunoblotting, the following primary antibodies
were used: p53 specific DO-1 (Santa Cruz, California,
USA 1:300), TRIM8 specific C-20 (Santa Cruz, California,
USA 1:200), N-MYC specific GTX81475 (Genetex 1:100),
p21 specific C-19 (Santa Cruz, 1:200), PPP2R2B specific
(Santa Cruz, California, USA 1:100) and Anti-Actin Ab-1
antibodies kit (Calbiochem, 1:2000). Bound primary anti-
bodies were visualized using Pierce ECL Western Blotting®
on a UVITEC Alliance LD2 Cambridge Camera.
The densitometry analysis has been performed using
“ImageJ”, a Java-based image-processing program. We
used the actin to normalize the data; the protein fold-
change has been calculated comparing the values of cells
transfected with anti-miR-17-5p or anti-miR-106b-5p to
the value of control cells transfected with control
miRNA.
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Results
miR-17-5p and miR-106b-5p expression levels are
up-regulated in ccRCC patients
In our previous paper, we demonstrated that TRIM8 is
down regulated in ccRCC patients, impairing p53-mediated
responses and resulting in chemo-resistance [7]. Here, to
elucidate the molecular mechanisms leading to this
gene expression alteration, we tested the possible cor-
relation with the expression levels of two miRNA, miR-
17-5p and miR-106b-5p, since they are up-regulated in
chemo/radio-resistant cancers and the miR-17-92 clus-
ter targets TRIM8 mRNA [8, 9, 13–15].
We first measured miR-17-5p and miR-106b-5p expres-
sion levels in the same ccRCC samples in which we found
TRIM8 down-regulation (Fig. 1a and b – Additional file 2:
Figure S1a; [7]). The expression levels of miR-17-5p were
significantly higher in tumours (T in Fig. 1a), compared to
their corresponding non-tumour tissue (NT in Fig. 1a)
(3.64-fold; p-value < 0.005), which held true for all the
sample pairs analysed. Considering the variation of miR-
17-5p expression in each tissue pair and Fuhrman grade,
no relevant variation was detected suggesting that the up-
regulation of miR-17-5p expression might be independent
from the severity of this type of tumour (Fig. 1a). On the
contrary, miR-106b-5p expression level appeared to be
dependent on the tumour grade, since it got significantly
higher only in G3 Fuhrman grade samples (Fig. 1b). When
miR-17-5p and miR-106b-5p expression levels were
compared to those of TRIM8 in the same sample, only
miR-17-5p showed a strong negative linear relationship
with TRIM8 (r = -0.7878; p-value < 0.0001), while miR-
106b-5p was not linear correlated to its target gene ex-
pression (r = -0.02684; p-value = 0.8694) (Additional file 2:
Figure S1c and d).
Also in colorectal HCT116 cells and ccRCC derived cell
line (RCC-Shaw) the expression levels of miR-17-5p and
miR-106b-5p were down-regulated compared to normal
human kidney HK-2 cells, in conjunction with an increase
of TRIM8 mRNA levels (Fig. 1c and d - Additional file 2:
Figure S1b). Intriguingly, the UOK-257 carcinoma cell line
(harbouring a mutant p53) showed miR-17-5p expression
levels comparable to cancer RCC-Shaw and HCT116 cells,
Fig. 1 miR-17-5p and miR-106b-5p expression in ccRCC samples. a, b miR-17-5p and miR-106b-5p expression in ccRCC samples and their paired
non-tumour tissues. The analysis was performed considering the Fuhrman grading of the tumour samples. Data are represented in box-and-whisker plots
showing median and 10th, 25th, 75th and 90th percentiles for each category of sample. Expression data were measured respect to one normal sample
chosen arbitrarily as calibrator and then normalized by the expression levels of U6 snRNA. **p-value < 0.005. c, d miR-17-5p and miR-106b-5p expression
in the colon cancer HCT116 (p53wt) cell line and in three different renal cell lines: the human proximal tubular epithelial cells HK-2, the human renal cell
carcinoma RCC-Shaw (p53wt) and the human renal carcinoma of BHD (Birt-Hogg-Dubè) origin UOK-257 cells (mutated-p53). Expression data
were measured respect to HK-2 sample chosen as calibrator, and normalized by the expression levels of U6 snRNA. **p-value < 0.005;
*** p-value < 0.001
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while miR-106b-5p expression levels were comparable to
non-cancer HK-2 cells (Fig. 1c and d), a condition similar
to that observed in G1-G2 Fuhrman grade patients (where
p53 was wild-type though).
Significantly, ccRCC tissues and their non-tumour
counterpart showed no differences at all in the expres-
sion levels of miR-106a-5p, belonging to the same miR-
17 “seed” family and whose “seed” region matched with
TRIM8-3’UTR (Additional file 3: Figure S2a).
Interestingly, we did not observe alterations of miR-
106a-5p, miR-17-5p and miR-106b-5p expression in
benign renal oncocytoma samples compared to non-
tumour matched epithelial tissues (Additional file 3:
Figure S2b), suggesting that only miR-17-5p and miR-
106b-5p up-regulation is a signature of a malignant
phenotype.
Altogether, these results clearly indicate a strong
correlation between TRIM8 mRNA expression and miR-
17-5p and miR-106b-5p levels, suggesting that these
miRNAs could mediate TRIM8 mRNA degradation.
TRIM8 3’UTR is a target of both miR-17-5p and miR-106b-5p
To demonstrate that miR-106b-5p as well as miR-17-5p
directly inhibit the expression of TRIM8, we first used
an in silico approach to identify the miR-106b-5p and
miR-17-5p-binding sequence in the TRIM8 3’UTR re-
gion by using Target Scan (Release7.0, August 2015)
[25], the database of conserved 3’UTR miRNA targets.
We found that both miRNAs seed regions perfectly
matched an evolutionarily conserved region in the
3’UTR of the TRIM8 mRNA (Fig. 2a), which we experi-
mentally tested by performing Luciferase Reporter assay.
We cloned the putative binding sites (wild-type or
suitably mutated) of miR-106b-5p and miR-17-5p down-
stream of the luc2 firefly luciferase gene, under the
control of the human PhosphoGlycerateKinase (PGK) pro-
moter (pMIR-3’UTR-TRIM8-wt or pMIR-3’UTR-TRIM8-
mut) and transfected them in the HK-2 and HCT116 cell
lines with Negative Control miRNA Mimic (Ambion),
miR-106b-5p, miR-17-5p, anti-miR-106b-5p, anti-miR-17-
5p, both miRNAs or both anti-miRNAs (Fig. 2b-e). The ef-
ficiency of the transfections was validated by RT-qPCR
(data not shown). The luciferase reporter assays demon-
strated that both miR-106b-5p and miR-17-5p significantly
suppressed the firefly luciferase activity of pMIR-
3’UTR-TRIM8-wt (2.63- and 2.44-fold in HK-2, 1.82-
and 2.6-fold in HCT116, respectively), whereas they failed
to work when the target site was mutated (Fig. 2b and c).
Fig. 2 Structure and functional characterization of the putative miR-17-5p/miR-106b-5p target identified in the TRIM8 3’UTR sequence. a Schematic
representation of the pMIR luciferase reporter construct containing the TRIM8 3’UTR sequence (wild-type or mutated) cloned downstream the Luciferase
gene. Below it is shown the sequence alignment between the miR-17-5p/miR-106b-5p “seed” sequence and the TRIM8 3’UTR, as well as the evolutionary
conservation across species. b, c, d, e Luciferase assays. The HK-2 and HCT116 cells were transfected with Negative Control miRNA Mimic, miR-17-5p or
miR-106b-5p (alone or together), anti-miR-17-5p or anti-miR-106b-5p (alone or together), along with pMIR luciferase reporter construct containing TRIM8
3’UTR (wt or mut). Cells were lysed and luciferase activity was determined as described in the Material and Methods section. Transfection
efficacy was normalized by Renilla Luciferase activity. Data represent the averages of at least three independent experiments with their
standard deviations. ** p-value < 0.005; *** p-value < 0.001
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The co-transfection of both miR-106b-5p and miR-17-5p
further decreased the luciferase activity (4.2-fold in HK-2
and 3.56-fold in HCT116 cells) (Fig. 2b and c), indicating
they may act synergistically. On the other side, the inhibi-
tion of both endogenous miR-106b-5p and miR-17-5p by
anti-miR-106b-5p and anti-miR-17-5p resulted in in-
creasing firefly luciferase activity of pMIR-3’UTR-
TRIM8-wt, unlike the mutant construct (Fig. 2d and e).
As p21 mRNA contains a binding site for miR-106b-
5p and miR-17-5p [26, 27], we cloned its 3’UTR in the
pMIR luciferase vector (pMIR-3’UTR-p21-wt) and used
it to gauge the specificity of both miRNAs activity
(Additional file 4: Figure S3a and b).
To further confirm our hypothesis, we analysed the
effect of miR-106b-5p or miR-17-5p overexpression or
repression by transient transfection of the specific anti-
miR-106b-5p and anti-miR-17-5p in HK-2, clear cell
Renal Carcinoma (RCC-Shaw) and colorectal HCT116
cell lines. RT-qPCR demonstrated that the overexpres-
sion of both miRNAs decreased TRIM8 mRNA steady
state levels and, coherently, increased cell proliferation
(Fig. 3a and b). On the contrary, the suppression of miR-
106b-5p or miR-17-5p by specific anti-miRNAs in-
creased TRIM8 expression levels with a reduction of cell
proliferation in all cell lines (Fig. 3c and d). The simul-
taneous expression of both miRNAs caused a further
decrease of TRIM8 mRNA levels (Fig. 3a), while their
simultaneous suppression further promoted TRIM8 ex-
pression (Fig. 3c). Similar results were obtained for p21
mRNA control target (Fig. 3e and f).
Altogether, our experiments demonstrated that TRIM8
is a direct target of miR-106b-5p as well as of miR-17-5p
and that their co-expression synergizes in decreasing
TRIM8 mRNA, eventually resulting in increased cell
proliferation (Fig. 3a-d).
Both miR-17-5p and miR-106b-5p link p53 to the N-MYC
pathway
The increase of miR-17-5p and of miR-106b-5p (such as
that we observed in G3 stage renal carcinomas, Fig. 1a
and b) might account for a TRIM8 deficit, possibly re-
sponsible for p53 inactivation even in the absence of p53
mutations. Indeed, miR-17-92 cluster and MCM7 gene,
this latter containing the miR-106b-25 cluster, are tran-
scriptionally activated by N-MYC, which in turn is
negatively regulated by miR-34a, whose expression is
regulated by p53 [17–20]. We hence tested if the inhib-
ition of these two miRNAs by specific anti-miRNAs would
lead to p53 reactivation and to p53-dependent N-MYC
destabilization through miR-34a up-regulation [17, 20].
The HK-2 (normal kidney cells), the RCC-Shaw
(ccRCC-derived cell line with wt-p53), the UOK-257
Fig. 3 Effects of overexpression/silencing of miR-17-5p and miR-106b-5p on TRIM8 and p21 expression and cell proliferation. a, c, e, f Expression
levels of TRIM8 and p21 were measured by RT-qPCR in HK-2, RCC-Shaw and HCT116 cells transfected with Negative Control miRNA Mimic, miR-17-5p
or miR-106b-5p (alone or together) anti-miR-17-5p or anti-miR-106b-5p (alone or together). Relative expression ratios were measured respect to the
sample transfected with the Negative Control miRNA Mimic and normalized by the expression levels of RPL13 (* p-value < 0.01; ** p-value < 0.005).
b, d Cell proliferation was measured by MTT reduction assay in HK-2, RCC-Shaw and HCT116 transfected with Negative Control miRNA Mimic, miR-17-5p
or miR-106b-5p (alone or together), anti-miR-17-5p or anti-miR-106b-5p (alone or together). Measurements were normalized respect to the sample
transfected with the Negative Control miRNA Mimic. Data are shown as the average with standard deviation of at least 3 independent
experiments (** p-value < 0.005; *** p-value < 0.001)
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cells (RCC cell line with mutated p53) and HCT116
(colorectal cancer with wt-p53) were transfected with
anti-miR-17-5p and anti-miR-106b-5p. The efficiency
of the anti-miRNAs transfections was validated by
RT-qPCR (Additional file 5: Figure S4a and b). HK-2,
RCC-Shaw and HCT116 cells, but not p53-mutant
UOK-257 cells, showed a relevant increase of TRIM8
mRNA and protein levels (Fig. 4a-c and Additional
file 6: Figure S5a and b). Accordingly, only in p53wt
cell lines, i.e. HK-2, RCC-Shaw and HCT116, p53 became
stabilized, miR-34a and p21 levels increased, while N-
MYC protein levels sensibly dropped (Fig. 4b-e and
Additional file 6: Figure S5a and b). In UOK-257 cells,
upon anti-miR-17-5p overexpression, p21 protein expres-
sion increased 2.3 fold compared to the control cells coher-
ently with mRNA expression (Fig. 4b and e - Additional
file 6: Figure S5a). This increase in p21 expression seems
to be p53-independent since we did not observe any in-
crease of p53 protein upon anti-miR-17-5p overexpression
(Adiitional file 6: Figure S5a).
As a final important result of miR-17-5p and miR-106b-
5p knocking-down, RCC and HCT116 cell proliferation
rate decreased as demonstrated by MTT and colony-
forming assays (Fig. 3d - Additional file 5: Figure S4c).
These results clearly depict a novel pathway through
which the overexpression of miR-17-5p and its paralo-
gue miR-106b-5p inhibits TRIM8, leading, on one hand,
to the de-stabilization of the p53 tumour suppressor
protein and, on the other hand, to the activation of the
N-MYC oncogene, turning on cancer cells proliferation
(Fig. 5a). A feed-forward loop is thus created, whereby
N-MYC fosters its own protein expression via the inhib-
ition of TRIM8 mRNA by promoting miR-17-5p and
miR-106b-5p expression (Fig. 5a). Conversely, by inhibit-
ing the action of miR-17-5p and miR-106b-5p on TRIM8,
p53 becomes stable and activates miR-34a expression,
which in turn quenches the N-MYC protein (Fig. 5b).
Anti-miR-17-5p and anti-miR-106b-5p render chemotherapy
effective
The low chemotherapy response characterising ccRCC
and CRC prompted us to investigate whether miR-17-5p
and miR-106b-5p might contribute to the chemotherapy
Fig. 4 miR-17-5p and miR-106b-5p link p53 to the N-MYC pathway. a, d, e Expression levels of TRIM8, p21 and miR-34a were measured by RT-qPCR in
HK-2, RCC-Shaw, UOK-257 and HCT116 transfected with Negative Control miRNA Mimic, anti-miR-17-5p or anti-miR-106b-5p. Relative expression ratios
were measured respect to the sample transfected with the Negative Control miRNA Mimic and normalized by the expression levels of RPL13 for TRIM8
and p21, and by the expression level of U6 snRNA for miR-34a (** p-value < 0.005; *** p-value < 0.001). b, c Western blotting analysis of p53,
TRIM8, N-MYC and p21 proteins were measured in the indicated cell lines transfected with Negative Control miRNA Mimic, anti-miR-17-5p or
anti-miR-106b-5p. Western blot of Actin was conducted as control. Data are shown as the average with standard deviation of at least 3 independent
experiments (** p-value < 0.005; *** p-value < 0.001)
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resistance due to the TRIM8 protein loss, in the two
paradigmatic models of these cancers.
To address this critical question, renal HK-2, RCC-Shaw
and UOK-257 cells were transfected with control miRNA,
anti-miR-17-5p or anti-miR-106b-5p and treated with
Nutlin-3 (N) and Cisplatin (C), which induce p53-
dependent cell cycle arrest in tumours with wild type p53.
Moreover we treated the cells also with Sorafenib (S) or
Axitinib (A), belonging to the class of tyrosine kinases in-
hibitors (TKIs) that are currently the most successful class
of drugs used in the treatment of renal, hepatocellular car-
cinoma, colorectal and thyroid cancer in adults [28–36].
The efficiency of the anti-miRNAs transfections was vali-
dated by RT-qPCR (Additional file 7: Figure S6a-f). MTT
proliferation and colony suppression assays demonstrated
that all the chemotherapeutic drugs used significantly re-
duced HK-2 cell proliferation rate, but had no effect at all
on both RCC-Shaw and UOK-257, which have in common
inactivated p53, the first due to TRIM8 deficit, the
second to a mutation in the TP53 gene itself (Fig. 6a-c -
Additional file 7: Figure S6g-i). Conversely, both anti-
miR-17-5p and anti-miR-106b-5p induced a significant
reduction in proliferation rate in RCC-Shaw and in HK-
2 cells, but not in UOK-257 cells, which became more
pronounced when cells were treated with chemothera-
peutics (Fig. 6a-c).
Noteworthy, RT-qPCR demonstrated that in RCC-
Shaw cells all the drugs induced a great increase of miR-
17-5p and weaker of miR-106b-5p expression levels
(Additional file 7: Figure S6b and e). This effect would
further repress TRIM8 and p21, contributing positively
to the growth of the tumour and to the onset of chemo-
resistance (Fig. 6a-c - Additional file 7: Figure S6g-i).
Consistently with the cell proliferation decrease upon
anti-miR-17-5p and anti-miR-106b-5p overexpression,
only in p53wt background, but not in p53-mutated
UOK-257 cells, TRIM8 protein levels raised, p53 became
stabilized and promoted p21 and miR-34a transcription,
in turn decreasing N-MYC protein levels (Fig. 6d-f and
Additional file 8: Figure S7a-i).
As stated before, colorectal HCT116 cells show higher
expression level of TRIM8 and coherently lower miR-
17-5p and miR-106b-5p expression levels than RCC-
Shaw cells (Fig. 1c and d - Additional file 2: Figure S1b).
Even though chemotherapeutic drugs are able to reduce
cell proliferation rate, this reduction became more pro-
nounced when we increased TRIM8 and p53 proteins
levels by transfecting anti-miR-17-5p or anti-miR-106b-
5p (Fig. 7a-b), leading to miR-34a up-regulation and N-
MYC decrease (Fig. 7b - Additional file 9: Figure S8a-f ).
Altogether, these experiments demonstrated that anti-
miR-17-5p and anti-miR-106b-5p increase the efficacy of
chemotherapy treatments in resistant cancer cell lines.
Next, we tested if TRIM8, among all the targets regu-
lated by miR-17-5p, was pivotal to trigger cell sensitivity
to chemotherapy. To tackle this issue, RCC-Shaw cells
were transfected with Negative Control miRNA Mimic
(Ambion), anti-miR-17-5p plus pRS control vector or
anti-miR-17-5p plus specific TRIM8 short hairpins (pRS-
shRNA-TRIM8) and treated with chemotherapeutics.
Fig. 5 Schematic representation of the opposite p53-TRIM8 and N-MYC-miR17-5p/miR106b-5p networks in cellular response to treatments. a, b
Schematic representation of the molecular pathway that shows how TRIM8 recovery in TRIM8-deficient cells reactivates the p53 tumour suppressor
pathway and blunts the N-MYC oncogenic activity
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As shown in Fig. 8a-b and in Additional file 10:
Figure 9a-d, anti-miR-17-5p plus control shRNA
blocked cell proliferation because TRIM8 and p53 ex-
pression levels were increased, p21 and miR-34a were
transactivated by p53, and N-MYC was destabilized.
On the contrary, anti-miR-17-5p plus specific TRIM8
short hairpin failed to stall cell proliferation because
p53 was not stabilized by TRIM8, and was therefore
no longer able to transactivate p21 and miR-34a
(Fig. 8b - Additional file 10: Figure S9a-d). Accordingly,
N-MYC was still present (Fig. 8b). The successful
neutralization of miR-17-5p by anti-miR-17-5p was dem-
onstrated by the stabilization of one of its targets, i.e.
PPP2R2B (Protein Phosphatase 2 Regulatory subunit B,
beta) (Fig. 8b) [37].
These results led to the conclusion that TRIM8,
among all miR-17-5p targets, is pivotal in controlling
cell sensitivity to chemotherapy. Therefore, the effective-
ness of anti-miR-17-5p and anti-miR-106b-5p in rendering
the cells sensitive to chemotherapeutic drugs may be ex-
plained by their capability to increase TRIM8 mRNA
steady state levels.
TRIM8 overexpression blocks cell proliferation of human
tumour xenografts in nude mice
Based on the in vitro experiments, we hypothesized that
TRIM8 over-expression might inhibit tumour growth in
vivo, and attempted to demonstrate it by injecting hu-
man cancer cells into nude mice. We next treated the
tumours generated by administering TRIM8 or RING-
TRIM8, since we demonstrated that the RING domain
of TRIM8 alone is responsible for both p53 stabilization/
activation and MDM2 degradation [2]. We did not treat
tumours with anti-miR-17-5p because its inhibitory ef-
fects on tumour growth have been reported [26], while
our aim here was to point out the critical role of TRIM8
on tumour growth. To treat cancer cells with TRIM8 or
RING-TRIM8, we devised a strategy based on the use of
recombinant replication-incompetent adenoviruses. Hence,
three recombinant adenoviruses expressing HA-TRIM8,
HA-RING-TRIM8 or LacZ (as control) were generated.
To generate xenografts, we decided to use the meta-
static colon cancer HCT116 (p53+/+) cell line, which
shows a high tumorigenic potential and whose growth
kinetics in nude mice are well known [38]. HCT116
Fig. 6 Anti-miR-17-5p and anti-miR-106b-5p render chemotherapy treatments effective in ccRCC. a, b, c Cell proliferation by MTT reduction assay
in HK-2 (p53 wt), RCC-Shaw (p53 wt), and UOK-257 (mutated p53) transfected with Negative Control miRNA Mimic, anti-miR-17-5p or anti-miR-
106b-5p, and treated with Nutlin-3 (N)(10 μM), Cisplatin (C)(7.5 μM), Sorafenib (S)(10 μM), Axitinib (A)(10 μM) or drug-untreated cells(-). For each
cell line, drug-untreated sample transfected with control miRNA has been used as calibrator (fold 1.0). Cells transfected with anti-miR-17-5p or
anti-miR-106b-5p, or with control miRNA and treated with the different drugs have been normalized with respect to this calibrator. Data are
shown as the average with standard deviation of at least 3 independent experiments (** p-value < 0.005; *** p-value < 0.001). d, e, f Western
Blotting of the indicated proteins in HK-2 (control), RCC-Shaw and UOK-257 after transfection with Negative Control miRNA Mimic, anti-miR-17-5p,
anti-miR-106b-5p without drug (-) or after chemotherapeutic drug treatment with Nutlin-3 (N)(10 μM), Cisplatin (C)(7.5 μM), Sorafenib (S)(10 μM) or
Axitinib (A)(10 μM). Western blot of Actin was conducted as control
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cultured cells were injected subcutaneously in nude mice
and tumours thereby generated were treated by each of
the three recombinant adenoviruses administered twice
a week for three weeks. Eventually, tumours were mea-
sured by caliper at the same time.
As shown in Fig. 9a, the xenograft growth curves re-
vealed that the size of the tumours treated with Ad-HA-
TRIM8 or Ad-HA-RING remained unchanged and, at the
end of the experiment, they displayed mainly the same size
they had at the moment of injection. Conversely, the con-
trol masses injected with the LacZ recombinant adenovirus
grew with an exponential trend (Fig. 9a). The effect of the
treatment is evident also in the size and weight of the
masses that were markedly smaller than the control
ones (Fig. 9b - Additional file 11: Figure S10a). As we
observed in vitro, molecular analyses of the excised
masses confirmed p53 stabilization following exogenous
HA-TRIM8/RING expression, miR-17-5p down-regulation
and, at the same time, the up-regulation of miR-34a
(Fig. 9c-e - Additional file 11: Figure S10b).
These evidences confirmed in vivo the pathway we
identified in vitro, with TRIM8 emerging as key actor of
the activation in the p53-(miR-34a)-(N-MYC)-(miR-17)
family.
Moreover, these results strongly suggest the crucial
role of TRIM8 protein in preventing tumour growth
in vivo.
Discussion
In this paper, we describe for the first time how TRIM8
plays a crucial role in p53 activation and in N-MYC
quenching in a complex signalling involving the miR17
family. Moreover, we demonstrate that a TRIM8 deficit,
due to miR-17-5p/miR-106b-5p up-regulation, contributes
to oncogenesis and chemo-resistance.
We used two paradigmatic models of chemo-resistant
cancers: Renal Cell Carcinoma (RCC) and Colorectal
Cancer (CRC). RCC is the seventh most common neo-
plasm in men and the ninth most commonly occurring
in women. It is not responsive to neither chemotherapy
nor radiation therapy when metastases are already
present and is not possible to perform surgery for ap-
proximately 30% of all RCC cases [39]. CRC is one of
the leading cause of cancer mortality worldwide and
shows poor prognosis in advanced forms because of the
high rate of resistance to radiotherapy or chemotherapy,
which leads to recurrence, metastasis and death [40, 41].
Previously, we demonstrated that TRIM8 is down-
regulated in ccRCC, impairing p53-mediated responses
to chemotherapeutic drugs [7]. This deficit is partially
due to the loss of TRIM8 heterozygosity, but we did not
exclude other additional mechanisms, such as epigenetic
silencing. Here we report an inverse correlation between
miR-17-5p and TRIM8 expression in vivo. In patients with
a more aggressive tumour behaviour (G3 Fuhrman grade)
Fig. 7 Anti-miR-17-5p and anti-miR-106b-5p render chemotherapy treatments effective in CRC. a Cell proliferation by MTT reduction assay in
HCT116 (p53 wt) cells transfected with Negative Control miRNA Mimic, anti-miR-17-5p or anti-miR-106b-5p, and treated with Nutlin-3 (N)(10 μM),
Cisplatin (C)(7.5 μM), Sorafenib (S)(10 μM), Axitinib (A)(10 μM) or drug-untreated cells(-). For each cell line, drug-untreated sample transfected with
control miRNA has been used as calibrator (fold 1.0). Cells transfected with anti-miR-17-5p or anti-miR-106b-5p, or with control miRNA and treated
with the different drugs have been normalized with respect to this calibrator. Data are shown as the average with standard deviation of at least 3
independent experiments (** p-value < 0.005; *** p-value < 0.001). b Western Blotting of the indicated proteins in HCT116 cells after transfection
with Negative Control miRNA Mimic, anti-miR-17-5p, anti-miR-106b-5p without drug (-) or after chemotherapeutic drug treatment with Nutlin-3
(N)(10 μM), Cisplatin (C)(7.5 μM), Sorafenib (S)(10 μM) or Axitinib (A)(10 μM). Western blot of Actin was conducted as control
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we observed also a significant increase of miR-106b-5p,
but not miR-106a-5p, belonging both to the same miR-
17 seed-family. In patients affected by colorectal cancer,
neuroblastoma, breast and pancreatic cancer, it has
been extensively reported that miR-17-5p and miR-
106b-5p are overexpressed and are capable to confer
chemo-resistance [14, 15, 42, 43].
A shared feature between these two miRNAs, in
addition to the seed region, is that their transcription is
promoted by the oncoprotein N-MYC. Indeed, N-MYC
transactivates the miR17-92 cluster and may be consid-
ered a bona fide activator of the miR-106b-25 cluster,
since the MCM7 gene (mini-chromosome maintenance)
is transactivated by N-MYC [18, 19]. Of note, the miR-
106b/25 cluster is located exactly within intron 13 of the
MCM7 gene. MCM7 protein possesses the vital function
of “licensing” DNA synthesis during the transition from
G1 to the S phase. Both miRNAs clusters, in turn,
down-modulate different targets, beside TRIM8, such as
the tumour suppressors p21 and PTEN, hence contribu-
ting to tumorigenesis [14, 15]. Nevertheless, among all
the targets regulated by miR-17-5p, we demonstrated that
TRIM8 is pivotal to trigger cell sensitivity to chemotherapy.
In mammalian cells, MYC proteins belong to three
distinct gene families of transcription factors, namely C-
MYC, L-MYC and N-MYC. Their powerful oncogenic
fame derives from their frequent deregulation in a myr-
iad of human cancers and from a series of activities that
place MYC at the nexus of cell growth, proliferation,
metabolism, and genome stability [16]. MYC proteins
are subject to stringent control at every step of their ex-
pression. There are several potential ways by which can-
cer cells deregulate MYC, leading all to overexpression
of MYC proteins and their disconnection from the
critical signalling processes that normally keep it in
check. C-MYC is overexpressed in many different can-
cers; L-MYC is most often overexpressed in small cell
lung carcinomas, while N-MYC is most frequently over-
expressed in solid cancers of neural origin, as neuro-
blastoma and glioma. Only very few studies reported the
up-regulation of C-MYC pathway in ccRCC, even with-
out MYC amplification [44]. Notably, no detailed studies
Fig. 8 TRIM8 is pivotal in controlling chemotherapy cell sensitivity. a Cell proliferation by MTT reduction assay in RCC-Shaw transfected with
Negative Control miRNA Mimic or anti-miR-17-5p plus control short hairpin-RNA (control shRNA) or specific short hairpin against TRIM8
(shRNA-TRIM8) (** p-value < 0.005). After transfection the cells were treated with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM), Sorafenib (S)
(10 μM), Axitinib (A) (10 μM) or drug-untreated cells(-). For each cell line, drug-untreated sample transfected with control miRNA has been
used as calibrator (fold 1.0). Cells transfected with anti-miR-17-5p plus control shRNA or shRNA-TRIM8, or with control miRNA and treated with
the different drugs have been normalized with respect to this calibrator. b Western blotting analysis of the indicated proteins in RCC-Shaw
transfected with Negative Control miRNA Mimic or anti-miR-17-5p plus control short hairpin-RNA or specific short hairpin against TRIM8
(shRNA-TRIM8). After transfection the cells were treated with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or
drug-untreated cells (-). Western blot of Actin was conducted as control
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on the biological and clinical significance of N-MYC
have been reported for ccRCC and CRC thus far, to the
best of our knowledge.
Here we showed that the up-regulation of miR-17-5p
and miR-106b-5p leads to TRIM8 deficit, which in turn
leads to failure of p53 protein activation, preventing the
cells response to chemotherapy. Surprisingly, RT-qPCR
demonstrated that RCC cells treated with chemothera-
peutic drugs showed an inexplicable increase of miR-17-
5p and miR-106b-5p expression levels (Additional file 7:
Figure S6b and e) that in addition to keeping low TRIM8
protein levels, also keeps low the levels of crucial cell
cycle inhibitors such as p21 and PTEN [14, 15].
Previously, we observed that in ccRCC cell lines, dif-
ferently from other cell lines, TRIM8 do not promote
degradation of MDM2, the main negative regulator of
p53 [7]. With respect to this, it was demonstrated that
N-MYC up-regulates baseline levels of MDM2, inhibiting
p53-triggered apoptosis in neuroblastoma [45]. In this sce-
nario, TRIM8 recovery via miR-17-5p and miR-106b-5p
silencing seems to be a winning move as it renders
effective the tumour suppressor activity of p53, pro-
moting the transcription of miR-34a that knocks out
the oncogenic potential of N-MYC. Therefore we dem-
onstrated that, by counteracting the action of miR-17-
5p and miR-106b-5p by specific anti-miRs, the cells
regained sensitivity to chemotherapeutic treatments.
Significantly, cells became sensitive not only to Sorafenib
and Axitinib, which are among Tyrosine Kinase Inhibitors
currently in use for treatment of both renal and colorectal
carcinoma [28, 30, 32, 34, 35], but also to Nutlin-3 and
Cisplatin. This suggests that with the TRIM8-mediated re-
covery of the p53 tumour suppressor activity, a broader
spectrum of chemotherapeutic agents may be taken into
consideration to blunt tumorigenicity. Indeed, it is known
that Nutlin-3 enhances the efficacy of Sorafenib in renal
cell carcinoma, pointing to synergistic effects of these two
drugs in the treatment of this cancer [21].
Finally, the suppression of tumour cell proliferation
in mice xenografts provides conclusive evidence of
the TRIM8 role in mediating the p53 response in
tumours.
Fig. 9 Treatment of xenograft tumours in vivo with recombinant adenovirus expressing HA-TRIM8, HA-RING or LacZ (Control). a Growth curves
of xenograft tumours in nude mice treated for 3 weeks. The volume of the tumours was measured two times weekly (**** p- value <0.0005).
b Tumour masses weight at the moment of the tumour excision in treated (HA-TRIM8, HA-RING) vs. control (LacZ) samples (** p-value < 0.005). c, d, e
The stabilization of p53, miR-34a and down-regulation of miR-17-5p in xenografts treated with HA-TRIM8, HA-RING (T1-T5) or LacZ (C1-C3) was
demonstrated by western blotting analysis of p53 (Actin was used as loading control) and by RT-qPCR on miR-17-5p (* p-value < 0.05) and
miR-34a expression (* p-value < 0.05). The bars represent the Standard Error of the Mean
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Conclusions
In this paper, we report that low expression levels of
TRIM8 are an adverse prognostic factor. Our studies in-
crease the understanding of the molecular mechanisms
underlying the malignant features of chemo-resistant
tumours, suggesting molecular criteria for selecting tar-
geted therapies. The paradigm for cancer treatment has
evolved from relatively non-specific cytotoxic agents to
selective, mechanism-based therapeutics. Therefore, un-
derstanding how cancer cells lose control of MYC expres-
sion and p53 tumour suppressor activities is immensely
important in terms of staging cancers, predicting out-
comes to designed therapies.
Potential therapeutic applications that target miR-17-
5p/miR-106b-5p using specific anti-miRNAs should be
considered more closely for chemo-resistant tumours.
Additional files
Additional file 1: Table S1. Main characteristics of patients affected by
clear cell Renal Cell Carcinoma (ccRCC) and renal oncocytoma (RO). The
anagraphic (gender and age) and clinical (Fuhrman grade) data are
reported. (XLSX 65 kb)
Additional file 2: Figure S1. (a) TRIM8 expression in ccRCC samples (T)
and their paired non-tumour tissues (NT). The analysis was performed
considering the Fuhrman grading of the tumour samples. Data are
represented in box-and-whisker plots showing median and 10th, 25th,
75th and 90th percentiles for each category of sample. Expression data
were measured respect to one normal sample chosen arbitrarily as calibrator
and then normalized by the geometric mean of RPL13 and ACTB relative
expression ratios. The bars represent the Standard Error of the Mean. (b) TRIM8
expression in three different renal cell lines: the human proximal tubular
epithelial cells HK-2, the human renal cell carcinoma RCC-Shaw (p53wt) and
the human renal carcinoma of BHD (Birt-Hogg-Dubè) origin UOK-257 cells
(mutated-p53) and the colon cancer HCT116 (p53wt) cell line. Expression data
were measured respect to HK-2 sample chosen as calibrator, and normalized
by the expression levels of RPL13. **p-value < 0.005; *** p-value < 0.001. (c, d)
Linear regression plots of miR-17-5p and miR-106b-5p expression levels
compared with TRIM8 expression levels in ccRCC samples. On the x-axis the
Ct of TRIM8 minus the arithmetic mean of Cts calculated for ACTB and RPL13
(used as housekeeping genes in RT-qPCR analysis) is reported, while the y-axis
shows the Ct of miR-17-5p/miR-106b-5p minus the Ct of U6 snRNP (used to
normalize miRNAs expression levels). The value of the correlation coefficient “r”
and the p-value are indicated on the graph. Dots are coloured differentially
according to the sample type: grey for non-tumour samples, green for
Fuhrman Grade 1 samples, orange for Fuhrman Grade 2 samples and
yellow for Fuhrman Grade 3 samples. (PDF 186 kb)
Additional File 3: Figure S2. (a) miR-106a-5p expression in ccRCC samples
(T) and their paired non-tumour tissues (NT). The analysis was performed
considering the Fuhrman grading of the tumour samples. Data are
represented in box-and-whisker plots showing median and 10th, 25th,
75th and 90th percentiles for each category of sample. Expression data
were measured respect to one normal sample chosen arbitrarily as
calibrator and then normalized by the expression levels of U6 snRNA.
The bars represent the Standard Error of the Mean. It is also reported
the sequence alignment between the miR-106a-5p “seed” sequence
and the TRIM8 3’UTR. (b) miR-106a-5p, miR-17-5p and miR-106b-5p expression
in 4 oncocytoma samples (T) and their paired non-tumour tissues (NT). Data
are represented in box-and-whisker plots showing median and 10th, 25th,
75th and 90th percentiles for each category of sample. Expression data were
measured respect to one normal sample chosen arbitrarily as calibrator and
then normalized by the expression levels of U6 snRNA. The bars represent the
Standard Error of the Mean. (PDF 79 kb)
Additional file 4: Figure S3. (a, b) Luciferase assay. The HK-2 and the
HCT116 cells were transfected with Negative Control miRNA Mimic,
miR-17-5p, miR-106b-5p, anti-miR-17-5p or anti-miR-106b-5p, along
with pMIR luciferase reporter construct containing p21 3’UTR. Cells were
lysed and luciferase activity was determined as described in the Material
and Methods section. Transfection efficacy was normalized by Renilla
Luciferase activity. Data represent the averages of at least three independent
experiments with their standard deviations. ** p-value < 0.005;
*** p-value < 0.001. (PDF 64 kb)
Additional file 5: Figure S4. (a, b) Expression levels of miR-17-5p and
miR-106b-5p were measured by qPCR in HK-2, RCC-Shaw, UOK-257 and
HCT116, transfected with Negative Control miRNA Mimic, anti-miR-17-5p
or anti-miR-106b-5p. Relative expression ratios were measured respect to
the sample transfected with the Negative Control miRNA Mimic and
normalized by the expression level of U6 snRNA. The bars represent the
Standard deviation of the Mean. (c) Colony suppression assays. Cell
growth was measured in HK-2, RCC-Shaw, UOK-257 and HCT116 cells
transfected with Negative Control miRNA Mimic, anti-miR-17-5p or
anti-miR-106b-5p. (PDF 1350 kb)
Additional file 6: Figure S5. (a-b) Densitometry analysis of p53, Trim8,
N-MYC and p21 proteins in HK-2, UOK-257, RCC-Shaw and HCT116 cells
transfected with negative control miRNA Mimic, anti-miR-17-5p (a) or
anti-miR-106b-5p (b). The relative amounts of proteins, reported in the
table below the western blotting, have been calculated normalizing to
actin and calibrating to the respective control. (PDF 925 kb)
Additional file 7: Figure S6. (a-f) Expression levels of miR-17-5p and
miR-106b-5p were measured by RT-qPCR in HK-2, RCC-Shaw and UOK-257
cells, transfected with Negative Control miRNA Mimic, anti-miR-17-5p or
anti-miR-106b-5p, and treated for 24 h with Nutlin-3 (N) (10 μM), Cisplatin
(C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or drug-untreated
cells (-). Relative expression ratios were measured respect to the sample
transfected with the Negative Control miRNA Mimic and normalized by the
expression level of U6 snRNA. ** p-value < 0.005 (g-i) Colony suppression
assay. Cell growth were measured in HK-2, RCC-Shaw and UOK-257 cells
transfected with Negative Control miRNA Mimic, anti-miR-17-5p or
anti-miR-106b-5p, and treated for 24 h with Nutlin-3 (N) (10 μM), Cisplatin
(C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or drug-untreated
cells (-). (PDF 380 kb)
Additional file 8: Figure S7. (a-i) Expression levels of TRIM8, p21 and
miR-34a were measured by RT-qPCR in HK-2, RCC-Shaw and UOK-257 cells,
transfected with Negative Control miRNA Mimic, anti-miR-17-5p or anti-miR-
106b-5p, and treated for 24 h with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM),
Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or drug-untreated cells (-). Relative
expression ratios were measured respect to the sample transfected with the
Negative Control miRNA Mimic and normalized by the expression levels of
RPL13 for TRIM8 and p21, and by the expression level of U6 snRNA for miR-
34a. * p-value < 0.05; ** p-value < 0.005; *** p-value < 0.001. (PDF 220 kb)
Additional file 9: Figure S8. (a, b) Expression levels of miR-17-5p and
miR-106b-5p were measured by RT-qPCR in HCT116 cells, transfected
with Negative Control miRNA Mimic, anti-miR-17-5p or anti-miR-106b-5p,
and treated for 24 h with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM),
Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or drug-untreated cells (-).
Relative expression ratios were measured respect to the sample transfected
with the Negative Control miRNA Mimic and normalized by the expression
level of U6 snRNA. (c-e) Expression levels of TRIM8, p21, miR-34a and miR-17-
5p were measured by RT-qPCR in the RCC-Shaw cells transfected with
Negative Control miRNA Mimic or anti-miR-17-5p plus control short hairpin-
RNA (control shRNA) or specific short hairpin against TRIM8 (shRNA-TRIM8).
After transfection the cells were treated for 24 h with Nutlin-3 (N) (10 μM),
Cisplatin (C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or
drug-untreated cells (-). Relative expression ratios were measured respect
to the sample transfected with the Negative Control miRNA Mimic and
normalized by the expression levels of RPL13 for TRIM8 and p21, and by the
expression level of U6 snRNA for miR-34a and miR-17-5p. * p-value < 0.05;
** p-value < 0.005; *** p-value < 0.001 (f) Colony suppression assay. Cell growth
were measured in HCT116 cells transfected with Negative Control miRNA
Mimic, anti-miR-17-5p or anti-miR-106b-5p, and treated for 24 h with Nutlin-3
(N) (10 μM), Cisplatin (C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or
drug-untreated cells (-). (PDF 531 kb)
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Additional file 10: Figure S9. (a-d) Expression levels of TRIM8, p21,
miR-34a and miR-17-5p were measured by RT-qPCR in the RCC-Shaw
cells transfected with Negative Control miRNA Mimic or anti-miR-17-5p
plus control short hairpin-RNA (control shRNA) or specific short hairpin
against TRIM8 (shRNA-TRIM8). After transfection the cells were treated for
24 h with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM), Sorafenib (S) (10 μM),
Axitinib (A) (10 μM) or drug-untreated cells (-). Relative expression ratios
were measured respect to the sample transfected with the Negative Control
miRNA Mimic and normalized by the expression levels of RPL13 for
TRIM8 and p21, and by the expression level of U6 snRNA for miR-34a
and miR-17-5p. ** p-value < 0.005; *** p-value < 0.001. (PDF 150 kb)
Additional file 11: Figure S10. (a) Representative xenograft tumours at
the moment of the excision. (b) RT-qPCR demonstrating the expression
of the exogenous TRIM8 or RING-TRIM8. The histogram shows the ratio
between exogenous TRIM8 or RING-domain and the endogenous one.
The analysis was conducted measuring the expression of the HA epitope
and the expression of the total amount of RING domain in Control and
Treated samples. The bars represent the Standard Error of the Mean.
**p-value < 0.005. (PDF 650 kb)
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